The LiBBY trial found a purified THC-plus-CBD oil reduced agitation in hospice-eligible people with late-stage dementia. Researchers still need larger Phase 3 testing to confirm safety, generalizability, and infection risk for adult children making care decisions. LiBBY stands for Life's End Benefits of cannabidiol and tetrahydrocannabinol. It was a 12-week Phase 2 trial presented July 14, 2026, at AAIC 2026 in London, according to the Alzheimer's Association announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did LiBBY test?
- How much did agitation improve?
- Why do safety questions remain?
- What should adult children discuss with hospice?
What did LiBBY test?
LiBBY was a multicenter randomized double-blind placebo-controlled trial. It tested oral T2:C100, purified 2 mg THC plus 100 mg CBD in digestible oil twice daily. Participants took a half dose in week 1, then full dose 4 mg THC and 200 mg CBD twice daily in weeks 2-12.
The design and dosing were described in the Alzheimer's Association announcement. The trial enrolled 120 hospice-eligible people with Alzheimer's or other dementia and significant agitation. Mean age was 80, 55% were female, and visits occurred at home or residence across 10 U.S. sites, according to the Georgetown University summary.
How much did agitation improve?
Agitation means repeated restlessness, verbal outbursts, or physical actions that distress the person or others. LiBBY met its primary endpoint on the Cohen-Mansfield Agitation Inventory. Scores fell 10.61 points on THC/CBD versus 4.35 on placebo at week 2, a 6.27-point difference, with sustained separation through week 12.
The effect was reported by the NeurologyLive trial report. Global improvement reached 83.9% at week 2 and 87.2% at week 12 on treatment, versus 30.5% and 23.6% on placebo. That means nearly 9 in 10 treated participants improved by the clinician global measure.
Why do safety questions remain?
Overall adverse events were similar, 46.7% on THC/CBD versus 42.4% on placebo. Serious events were higher on treatment, 23.3% versus 11.9%, driven by serious infections. Serious infections occurred in 11.7% versus 1.7%, and deaths occurred in 13.1% versus 5.1%.
Investigators judged the deaths unrelated, as reported by the NeurologyLive trial report. Researchers say the findings apply only to the supervised purified formulation, not dispensary or over-the-counter cannabis. The NIA-funded ACTC program plus its 12-week open-label extension still require larger Phase 3 testing for safety and generalizability, according to the Pennington Biomedical Research Center update.
What should adult children discuss with hospice?
The product was experimental, not FDA-approved. End-of-life infection risk remains high, so families should not self-treat with cannabis products.
Use the next hospice or prescribing-clinician visit to review agitation options, benefits, and infection monitoring. Bring these items: Ask whether a clinical trial is available and what follow-up would involve. Bring a list of current sedatives, agitation triggers, and fever or infection signs to that visit.
- current agitation patterns, triggers, and safety concerns
- full medication and supplement list, including sleep aids and sedatives
- recent fevers, cough, urinary changes, wounds, or hospital visits
- goals for comfort, alertness, and where care will occur
You Might Also Like
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: What Researchers Still Need to Learn for Adult Children
- Safety Questions After the 2026 LiBBY Dementia Trial: What Researchers Still Need to Learn for Adult Children
- Repetitive Heading and Brain Health Findings at AAIC 2026: What Researchers Still Need to Learn for Adult Children
